کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2105988 1546388 2006 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Denileukin Diftitox as Prophylaxis against Graft-versus-Host Disease in the Canine Hematopoietic Cell Transplantation Model
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
Denileukin Diftitox as Prophylaxis against Graft-versus-Host Disease in the Canine Hematopoietic Cell Transplantation Model
چکیده انگلیسی

Denileukin diftitox (Ontak) was evaluated in combination with methotrexate (MTX) for preventing acute graft-versus-host disease (GVHD) in dogs given 9.2 Gy of total body irradiation and DLA-nonidentical hematopoietic cell grafts. Six dogs were given denileukin diftitox 9 μg/kg/day intravenously (IV) on days 2, 4, 5, 7, 8, and 10, in combination with MTX 0.4 mg/kg/day IV on days 1, 3, 6, and 11 after transplantation. Median survival of the dogs given MTX in combination with denileukin diftitox was 16 days (range, 13-18 days), similar to that of 35 historical controls given MTX alone (median survival, 20 days). Five of the 6 denileukin diftitox–treated dogs had clinical and pathological evidence of 3-system GVHD; 1 dog died of canine herpes virus infection without evidence of GVHD. In conclusion, denileukin diftitox did not prevent, mitigate, or delay acute GVHD in this stringent and predictive (with respect to outcomes in human patients) hematopoietic cell transplantation model.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: - Volume 12, Issue 9, September 2006, Pages 899–904
نویسندگان
, , ,